
FORXIGA is now A CLASS 1A FIRST-LINE THERAPY for all HFrEF patients in ESC 2021 HF guideline 14.11



TRANSFORM YOUR HEREF SOC WITH FORXIGA²



Risk of CV Death or Worsening of HF[†] (HR 0.74 [95% CI, 0.65, 0.85]; p<0.001)



Risk of Worsenina of HF^{†,‡}

(HR 0.70 [95% CI, 0.59, 0.831)



Risk of CV Mortality[‡] (HR 0.82 [95% CI, 0.69, 0.981)



All-cause Mortality§,II (HR 0.83 [95% CI. 0.71, 0.97])



No increased rates of major hypoglycemia vs placebo in DAPA-HF²

FORXIGA AS A SIMPLE ADD-ON TO HFrEF SOC1





10 MG 1 1 TABLET/DAY WITH NO TITRATION

CAN BE PRESCRIBED FOR PATIENTS AT THE FIRST OPPORTUNITY IN OR WITH

Existing HF Therapy and Diuretics

Common CV and T2D Medications ≥30 mL/min/1.73m²**

eGFR







- addition to the original indication for the treatment of insufficient controlled type 2 diabetes mellitus as an adjunct to diet and exercise, it has a new indication for reatment of symptomatic chronic heart failure with reduced ejection fraction:

 episode of worsening heart failure was either an unplanned hospitalization or an urgent visit resulting in intravenous therapy for heart failure.



CI=confidence interval. CV=cardiovascular. DAPA-HF-Dapagliflozin And Prevention of Adverse outcomes in Heart Failure. eGFR-estimated glomerular filtration rate. HF-heart failure. HFFF-HF with reduced ejection 2 diabetes.



CONSISTENT BENEFITS*

IN A BROAD RANGE OF HERE PATIENTS

Diabetes status3

Pint=0.80

hHF history4 P:...=0.08

> LVEF⁵ Pint=0.76

Baseline mortality risk6 Pint=0.71

HF etiology⁷ P_{int}=0.55

Baseline

NT-proBNP8 P_{int}=0.09

forxida. (dapaqliflozin)

Efficacy achieved in HFrÉF patients Health status outcomes9,1

Pint=0.52

Age¹⁰ Pint=0.76

SBP11

Pint=0.78

Renal function12 Pint=0.54

Background therapy¹³ P_{int}≥0.16

WHEN IT'S TIME TO INTENSIFY THE HFrEF REGIMEN. PRESCRIBE FORXIGA.

enefits refer to the reduction of in primary composite endpoint ardiovascular death or a worseni

heart failure. HFrEF=heart failure with reduced ejection tion. hHF=hospitalization for heart failure. LVEF=left ventricular tion fraction. NT=proBNP=N-terminal pro-B-type natriuretic peptide. =9ystolic blood pressure.

References: F.709034 Hzvg, Strag Resorbing Information, Nov. 2000. 2. Mediumy, J.M. et al., N. Engl. J.M.44, 2019;88 Hzvg. 503. 3. Revisit M.C. et al. JAMA. 2000;2031153-3184. d. Schallen INFO Resorbing of American Section (1978). The Schallen Reference of Amer

Alterviaced Prescribing Information (API)
FORMGA (slepagillatin)
FOR

Intended for Healthcare professionals only.

Pleases with constangued call actual examples of the property of

Forxiga® is the trademark of the AstraZeneca group of companies.



AstraZeneca Hong Kong Limited Unit 1-3, 11/F, 18 King Wah Road, North Point, Hong Kong Tel: (852) 2420 7388 Fax: (852) 2422 6788

